The Medical Letter on Drugs and Therapeutics
A New Japanese Encephalitis Vaccine (Ixiaro)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a new Japanese encephalitis vaccine (Ixiaro – Intercell/Novartis). It will replace JE-Vax (Sanofi Pasteur)1, which has had tolerability and safety problems and is no longer being manufactured.

EPIDEMIOLOGY — Japanese encephalitis (JE) virus is a mosquito-transmitted flavivirus endemic in many Asian countries. Clinical disease, which occurs in less than 1% of people infected, can lead to encephalitis, coma, serious neuropsychiatric sequelae and death. In Asia, clinical disease with JE has been estimated to occur in about 30,000 to 50,000 people each year, resulting in 10,000 to 15,000 deaths.2 However, only 4 cases of JE were reported in US residents between 1992 and 2008.3,4

EFFICACY – The immunogenicity of the new vaccine was established in a randomized, observer-blinded, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Japanese Encephalitis Vaccine (Ixiaro)
Article code: 1319b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian